AbCellera Results Presentation Deck

Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 сл PARTNERSHIPS 2 DISCOVERY PROGRAMS ADVANCE INTO PRECLINICAL AND CLINICAL DEVELOPMENT REGENERON FIRST candidate to advance into further preclinical development GPCR target 4 targets multi-year multiple indications undisclosed 1 MOLECULE ENTERED THE CLINIC Alzheimer's Disease

View entire presentation